Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Weekly primaquine plus dihydroartemisinin-piperaquine in vivax malaria with and without G6PD deficiency
ACTRN12613000003774Phase 4Not yet recruiting
- Sponsor
- National Centre for Parasitology, Entomology and Malaria Control
- Start
- Jan 2013
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 4, open-label trial of primaquine and dihydroartemisinin + piperaquine in malaria (2 arms), sponsored by National Centre for Parasitology, Entomology and Malaria Control. Primary endpoint: Completion of 8 weeks of primaquine without protocol-defined hematologic toxicity. Planned start Jan 2013; status: not yet recruiting.
02
Drugs
primaquinedihydroartemisinin + piperaquine
03
Conditions
malaria
Beyond the preview
Go deeper on ACTRN12613000003774.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12613000003774.